Oppenheimer Asset Management Inc. Has $15.10 Million Holdings in Gilead Sciences, Inc. $GILD

Oppenheimer Asset Management Inc. lifted its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.9% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,002 shares of the biopharmaceutical company’s stock after acquiring an additional 6,305 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings in Gilead Sciences were worth $15,096,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of GILD. GoalVest Advisory LLC grew its holdings in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Corundum Trust Company INC bought a new position in shares of Gilead Sciences in the third quarter worth about $26,000. Harbor Asset Planning Inc. acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $27,000. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $30,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the transaction, the insider owned 103,221 shares of the company’s stock, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction that occurred on Friday, November 28th. The shares were sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the transaction, the director owned 1,339 shares of the company’s stock, valued at $170,186.90. This trade represents a 67.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 373,037 shares of company stock valued at $50,731,512 over the last 90 days. Insiders own 0.27% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on the company. Leerink Partners upped their price objective on Gilead Sciences from $114.00 to $146.00 and gave the stock an “outperform” rating in a report on Friday, January 30th. Daiwa Securities Group boosted their target price on Gilead Sciences from $128.00 to $129.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. HSBC raised their price target on Gilead Sciences from $110.00 to $133.00 and gave the company a “hold” rating in a report on Wednesday, December 10th. Wall Street Zen cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Finally, Needham & Company LLC upped their target price on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $151.68 on Tuesday. The stock’s fifty day simple moving average is $127.92 and its 200 day simple moving average is $121.31. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $188.19 billion, a PE ratio of 23.52, a PEG ratio of 0.80 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $153.13.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.